Status:
RECRUITING
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
Lead Sponsor:
NHS Lothian
Conditions:
Localized Prostate Cancer
Low Risk Prostate Cancer
Eligibility:
MALE
Phase:
NA
Brief Summary
The investigators want to investigate whether it is possible to reduce the number of curative radiotherapy doses from 5 to only 3 for men with localized early prostate cancer. The aim of the study is ...
Detailed Description
Prostate cancer is the commonest male cancer and sadly more than 10,000 men die each year from the disease in the UK. This is actually a greater number than women who die from breast cancer each year ...
Eligibility Criteria
Inclusion
- low and favorable intermediate NCCN Criteria patients
- Prostate volume under 80cc
- IPSS under 20
- Q-max above 10cc per second and urinary residual less than 150mls
- No TURP
- No hip replacements
- No previous radiotherapy to the pelvis
- No active second malignancy except skin SCC or BCC for the last 2 years
- No history of inflammatory bowel disease
- No co-morbid illness that would make compliance to treatment difficult
- Able to give informed consent
Exclusion
- T3a or above
- Gleason 4+3=7
- PSA\>20ng/ml
Key Trial Info
Start Date :
November 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06117059
Start Date
November 1 2024
End Date
November 1 2027
Last Update
December 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NHS Lothian
Edinburgh, United Kingdom